LICENSE AGREEMENTLicense Agreement • November 9th, 2021 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”) dated as of August 6, 2021 (the “Execution Date”), is entered into between AOP Orphan Pharmaceuticals GmbH, an Austrian company having offices at Leopold-Ungar-Platz 2, 1190 Vienna, Austria (“AOP”) and Eagle Pharmaceuticals, Inc., a Delaware corporation having offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, United States (“Eagle”).
LICENSE AGREEMENT BETWEEN EAGLE PHARMACEUTICALS, INC. AND COMBIOXIN SALicense Agreement • November 9th, 2021 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (“Agreement”) dated as of August 19, 2021 (“Effective Date”), is entered into between Eagle Pharmaceuticals, Inc., a Delaware corporation having offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, United States (“Eagle”) and Combioxin SA, a Swiss corporation having offices at Route de la Corniche 5, 1066 Epalinges, Switzerland (“Combioxin”).
